A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Summary

This study was the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study was to see how GLPG1690 was tolerated in participants with systemic sclerosis and whether there were any side effects in a long-term treatment period.

Timeline

Start

2019-07-18

Primary completion

2021-04-13

Completion

2021-04-13

Drugs

Indications